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Use of distress and depression thermometers
to measure psychosocial morbidity
among southern European cancer patients
Abstract Goals of work: Recent
literature has indicated the need for
rapid evaluation of psychosocial is-
sues secondary to cancer. Because of
the problems of routine use of psy-
chometric instruments, short instru-
ments such as visual analogue scales
or one-item 0–10 scales have been
developed as valid assessment alter-
natives. Patients and methods: A
study was conducted to examine the
role of two 0–10 scales in measuring
emotional stress (distress thermome-
ter, DT) and depressed mood (mood
thermometer, MT), respectively, in a
multicenter study carried out in
southern European countries (Italy,
Portugal, Spain, and Switzerland). A
convenience sample of 312 cancer
outpatients completed the DT and MT
and the Hospital Anxiety Depression
Scale (HADS). Main results: DT
was more significantly associated
HADS anxiety than HADS depres-
sion while MT was related both to
HADS anxiety and depression. The
correlation of MT with HADS was
higher than DT. A cutoff point >4 on
the DT maximized sensitivity (65%)
and specificity (79%) for general
psychosocial morbidity while a cutoff
>5 identified more severe “caseness”
(sensitivity=70%; specificity=73%).
On the MT, sensitivity and specificity
for general psychosocial morbidity
were 85% and 72% by using the
cutoff score >3. A score >4 on the MT
was associated with a sensitivity of
78% and a specificity of 77% in
detecting more severe caseness.
Conclusions: Two simple instru-
ments, the DT and the MT, were
found to have acceptable levels of
sensitivity and specificity in detecting
psychosocial morbidity. Compared to
the HADS, however, the mood MT
performed better than the DT.
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Over the last 20 years, a burgeoning number of studies
have shown that cancer patients present high levels of
distress, which is associated to maladaptive coping and
impairment in social relationships. [1] However, far less
than 30% of cancer patients showing psychosocial prob-
lems are recognized in clinical settings by oncologists and
thus referred to proper sources of psychological support
[2, 3]. Several psychometric instruments, such as the
Hospital and Anxiety Depression Scale (HADS) [4–6],
the Brief Symptom Inventory (BSI) [7], the Profile of
Mood States (POMS) [8], and the Zung Depression In-
ventory [9] have been suggested as clinical tools to be
routinely used in cancer settings in order to improve the
detection of psychosocial morbidity, especially depres-
sion, and the referral of patients who resulted as “cases”
[10, 11]. Lack of time and lack of self-confidence in ex-
ploring psychosocial dimensions and in using psycho-
metric instruments have been raised by cancer physicians
as the most frequent barriers for not detecting and referring
patients [12].
Thus, brief screening instruments such as single-item
questions and 0–10 point scales have more recently been
suggested as a rapid, noninvasive, acceptable, and valid
alternative to psychometric instruments, especially in busy
cancer outpatient clinics. Within the National Compre-
hensive Cancer Network (NCCN), guidelines for the iden-
tification of psychosocial distress have been recently
proposed to be an integral part of routine clinical care in
cancer settings [13–16]. A score of 4 on a 0–10 distress
tool, the Distress Thermometer (DT), was proposed as the
most appropriate cutoff for identifying distressed patients
and referring them for psycho-oncology consultation. Roth
et al. [17], by using the HADS and the DT among prostate
cancer patients, found the DT to be useful in rapidly
detecting patients in need of more specific psychological
assessment. Jacobsen et al. [18], by studying 380 cancer
patients, showed that a cutoff of 4 on the DT yielded
optimal sensitivity and specificity in comparison with
“caseness,” as established by the HADS. They also found
the above-mentioned cutoff was useful in identifying pa-
tients reporting high levels of physical, emotional, prac-
tical, and family problems [18, 19].
More recently, cross-cultural data have been gathered
on the use of the DT in cancer settings. In a Japanese study
[20] carried out on 275 cancer patients, the sensitivity and
specificity of the DT in the detection of adjustment dis-
orders and major depression were reported to be 84% and
61%, respectively. The authors also showed that a com-
panion Impact 0–10 Thermometer (i.e., “What is the im-
pact of illness to you”) was useful, at a cutoff of 3, in
adding further clinical information.
However, some contrasting data and problems have also
emerged. In a large study of more than 1,000 cancer pa-
tients, the DT was associated to a larger extent with the
HADS anxiety dimension rather than HADS depression
dimension, with higher identification of cases of anxiety
rather than those who were depressed [21]. This suggests
the need to consider further simple tools, as in the study of
Akizuki et al. [20], in order to discriminate between psy-
chosocial dimensions and detect possible morbidity. Fur-
thermore, Muszbek et al. [22], examining the specificity
and sensitivity of the DT in comparison with the HADS
in Hungarian cancer patients, found problems in the trans-
lation of the word “distress” into their own language. They
used multiple words such as “feeling blue” and “feeling
bad,” but with the risk of measuring different dimensions.
Similar problems of translation or conceptualization from
English (e.g., fatalism, abnormal illness behavior) have
been reported by other countries, such as Italy and Spain,
where other psychosocial dimensions of cancer were ex-
amined from a cross-cultural perspective [23, 24]. However,
no study has examined the use of DT and its translated
versions in these countries. Thus, given the importance of
routinely assessing cancer patients’ emotional distress that,
along with pulse, temperature, respiration, blood pressure,
and pain, has been proposed to be considered as the “sixth
vital sign” [25], we considered it important to have more
information on this area from a cross-cultural point of
view.
This study is a part of a larger investigation (Southern
European Psycho-Oncology Study—SEPOS) that eval-
uated psychosocial implications of cancer in southern
European countries [26, 27] and the efficacy of a training
model in helping physicians to recognize their patients’
psychosocial morbidity [28]. The main purpose of the study
presented here was to assess the validity of two simple
instruments in cancer settings in a cultural context where




The study was conducted in three countries of the Europe-
an Union (EU), namely, Italy (Hospital S. Anna, Ferrara),
Spain (Hospital Duran i Reynals, Barcelona), and Portugal
(Hospital S. José, Lisbon), and in a non-EU country with a
similar cultural background, Switzerland (General Hospi-
tal, Lugano). A convenience sample of cancer outpatients
was invited to participate in the study. Enrollment criteria
entailed being outpatients with a diagnosis of cancer (at
any stage) between 6 months and 2 years and no cognitive
impairment due to disease or side-effects of treatment, as
evaluated both at the clinical level (orientation in time,
space and person, short-term memory) and through the
Mini Mental State Examination (cutoff=24) [29]. Further-
more, since the original study also had the aim of eval-
uating the ability of physicians to assess their patients’
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psychosocial morbidity, only patients reporting a score ≥80
on the Karnofsky Performance Status Scale (KPSS) [30]
were recruited. This was in order to avoid the possibility
of patients’ poor physical conditions negatively influenc-
ing the doctors’ ability to assess psychosocial disorders,
which are more complex to evaluate in the advanced stages
of illness [31]. However, the patients enrolled in the study
were representative of cancer patients seeking care at the
site of each respective center and region.
The study was approved by the ethical committee or
related boards of the hospitals. Each patient was informed
of the aim of the study, gave written consent to participate,
and was individually met by research psychologists in-
volved in the study. Each patient was given psychological
measures, which were explained in detail before being com-
pleted. The following instruments were used:
1. The HADS [32] was used to assess anxiety, depres-
sion, and total psychosocial morbidity (caseness). The
HADS was chosen both because it has been reported
to be a “gold standard” for evaluation of anxiety and
depression in cancer settings [5, 6] and because of the
need to replicate in a different cross-cultural context
the data obtained by other authors using the same
methodology [18, 19, 22]. The HADS is a 14-item
self-rated scale consisting of two subscales: anxiety
(seven items) and depression (seven items), which to-
gether yield a total HADS score. A cutoff of 8 on each
scale has been proposed for “likely or borderline cases”
of both anxiety and depression among cancer patients
while the cutoff of 11 has been reported to identify
more severe cases [5]. On the HADS total score, the
cutoff >14 has been shown to be the best predictor of
general psychosocial morbidity [33, 34] while the cut-
off of 19 has been shown to be the best predictor of
more severe caseness (e.g., major depression).
2. Two “emotional thermometers” were used to evaluate
the patient’s level of distress (DT) and depression (MT).
The DT was used according to NCCN guidelines on
distress management [13, 15] while depressed mood
(MT) was chosen in order to verify its relationship with
the dimension of mood. Each patient was asked to an-
swer the question “How distressed have you been
today and over the last week”? for the DT and to rate
their answer on a 0–10 scale (0=no distress; 10=extreme
distress). Likewise, they were asked to answer the
question “How depressed have you been today and
over the last week”? for the MT and to rate their
answer on a 0–10 scale (0=normal mood; 10=extreme
depression).
Statistical analysis
Distribution and frequency analyses were employed to de-
scribe the sample. Cronbach’s alpha was used to examine
reliability and internal consistency of the HADS. Corre-
lation analysis, Student’s t test, and ANOVA where used
when appropriate. Receiver operating characteristic (ROC)
analysis [35] was used to evaluate the diagnostic accuracy
of the DT and MT to detect cases identified by the HADS.
A series of ROC analyses were performed by using the
different DT and MT cutoff scores on the total score of
the HADS in order to measure the sensitivity, specificity,
and positive predictive values in discriminating between
cases and noncases, as identified by the HADS.
Results
Sociodemographic and clinical features of the sample
Three hundred and twenty-three patients were recruited.
Mean age was 57 years (SD 13.26); 69% (n=224) were
women and 21% (n=99) were men. Mean education was
9 years (SD 5.88). Most patients were married (n=233,
72%), and 41% were retired (n=133). The stage of the
disease was local (n=134, 41%), loco-regional (n=87,
27%), and metastatic (n=55, 17%). Almost half of the
sample was diagnosed as having breast cancer (n=154,
8%) (Table 1).
Table 1 Patient sociodemographic and clinical characteristics
Variables Characteristics Number (%)
Age (years): mean (SD) 57 (13.26)
Gender Male 99 (31)
Female 224 (69)
Diagnosis Breast cancer 154 (48)
Colorectal cancer 45 (14)
Lung cancer 18 (5)
Other tumors 106 (67)
Illness stage Local 134 (49)
Loco-regional 87 (31)
Metastatic 55 (20)
Education in years Mean (SD) 8.95 (5.88)
≥18 years 27 (9)
≤18 years 296 (81)
Marital status Married 233 (72)











Data concerning psychological measures
Complete questionnaires were available for 312 subjects.
Since the HADS was used in three different countries,
factor analysis was performed in order to assess the char-
acteristics and reliability of the scale. Two factors emerged
consisting of the same items as the original version (seven
items for the anxiety factor, factor loading between 0.44
and 0.78, Cronbach’s alpha=0.81; seven items for the de-
pression factor, factor loading between 0.49 and 0.79,
Cronbach’s alpha=0.81).
According to the established cutoff values of 8, 203
patients (65%) and 236 patients (75.6%) scored within the
normal ranges on anxiety and depression, respectively.
Fifty-five patients (17.6%) were borderline cases of anx-
iety, and 48 (15.4%) were borderline cases of depression
(cutoff <11). Fifty-four (17.3%) were cases on anxiety and
28 (9%) on depression (cutoff ≥11). With regard to general
psychosocial morbidity (HADS total score), 28.8% pa-
tients (n=90/312) emerged as being cases (cutoff >14) and
16.3% (51/312) as being more severe cases (cutoff=19).
DT correlated more significantly with HADS anxiety
(r=0.50, p=0.001) than depression (r=0.40, p=0.02). MT
correlated significantly both with HADS depression (r=0.61,
p=0.001) and HADS anxiety (r=0.56, p=0.001). In general,
MT showed more significant correlation scores with HADS
subscales and HADS single items than DT (Table 2). DT
and MT were significantly correlated (r=0.40, p=0.01).
With regard to sociodemographic and clinical variables,
no difference was found on the DT and MT according to
gender, stage of illness, and type of cancer (breast versus
other types). As far as the HADS is concerned, only
HADS depression was marginally related to age (r=0.16,
p=0.05) while no significant relationships were found
regarding the other sociodemographic and clinical vari-
ables explored.
ROC analysis
ROC was used to identify the optimal cutoff score on the
distress and depression thermometers in identifying case-
ness according to the HADS total score. By using the
HADS total score for general psychosocial morbidity, the
AUC was 0.77 (95% CI 0.72–0.83) for the DT and 0.83
(95% CI 0.78–0.88) for the MT. By using the more con-
servative HADS total score for more severe caseness, the
AUC was 0.78 for DT (95% CI 0.71–0.85), and 0.84 for
MT (95% CI 0.78–0.90). The optimal cutoff scores on
DT and MT for general psychosocial morbidity and more
severe caseness are presented in Figs. 1 and 2. A cutoff
score >4 maximized sensitivity and specificity of DT in
detecting general psychosocial morbidity (sensitivity=65%,
specificity=79%) while the cutoff score >5 maximized sen-
sitivity (70%) and specificity (73%) in detecting more
severe caseness. The cutoff score >3 on the MT was asso-
ciated with sensitivity of 85% and a specificity of 72%
in detecting general psychosocial morbidity while a score
>4was associated with a sensitivity of 78% and a specificity


















Fig. 1 Receiver operating characteristics (ROC) curve of the DT
(squares) and MT (circles) in detecting general morbidity according
to the Hospital Anxiety and Depression Scale (HADS) (cutoff >14)
Table 2 Correlation between the emotional thermometers [distress
thermometer (DT) and mood thermometer (MT)] and the Hospital
Anxiety Depression Scale (HADS)
HADS DT MT
Anxiety items
I feel tense or “wound up” 0.41 0.38
I get a sort of frightened feeling as if
something awful is about to happen
0.30 0.36
Worrying thoughts go through my mind 0.41 0.46
I can sit at ease and feel relaxed −0.37 −0.44
I get a sort of frightened feeling like
“butterflies” in the stomach
0.28 0.35
I feel restless, as if I have to be on the move 0.27 0.26
I get sudden feelings of panic 0.38 0.38
Depression items
I still enjoy the things I used to enjoy −0.25 −0.45
I can laugh and see the funny side of things −0.29 −0.41
I feel cheerful 0.31 0.56
I feel as if I am slowed down 0.28 0.31
I have lost interest in my appearance 0.28 0.37
I look forward with enjoyment to things −0.22 −0.51
I can enjoy a good book or TV program −0.24 −0.24
HADS anxiety 0.50 0.56
HADS depression 0.40 0.61
HADS total 0.51 0.65
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Discussion
In this study, we presented the validity of two easy-to-
administer emotional thermometers in examining two di-
mensions of psychosocial morbidity, namely, distress and
depressed mood, among cancer patients in southern Eu-
rope. The most important caveat to be considered when
discussing the data relates to the fact that the evaluation
of psychosocial morbidity was performed by using a psy-
chometric instrument, such as the HADS. Although we
followed the same methodology of other investigations
[18, 19, 21, 22] which detect caseness by using the HADS
only, because of its good factor structure and performance
in cancer settings [4–6], a more detailed psychiatric in-
terview [e.g., Structured Clinical Interview for DSM-IV
(SCID), Composite International Diagnostic Interview
(CIDI), Mini International Neuropsychiatric Interview
(MINI)] would have avoided the risk of patient misclassi-
fication. In fact, by using the HADS, 15–20% of patients
were shown to be false-positive or false-negative, respec-
tively, in different studies [4, 5]. However, in our inves-
tigation, the HADS appeared to have acceptable levels of
reliability and internal consistency. Furthermore, prelimi-
nary data examining the DT and the HADS compared with
the International Classification of Diseases, Tenth Revision
(ICD-10) in Italian cancer patients seem to confirm validity
of both psychological tools [36]. It also has to be con-
sidered that even gold standard psychiatric nosographic
systems [e.g., Diagnostic and Statistical Manual for Mental
Disorders-Fourth Revision (DSM-IV) and ICD-10] lack
criteria for the identification of some important dimensions
of psychosocial morbidity (e.g., health anxiety, demorali-
zation, irritable mood) in medically ill patients, including
cancer patients [37, 38]. Bearing these limitations in mind,
the findings of the study showed that both the DT and the
MT were useful in rapidly assessing psychosocial distress
in cancer patients in a different cultural area in comparison
with English-speaking countries. This underscores the
utility of simple instruments in their routine application in
cancer services.
Distress was related to a larger extent to HADS anxiety
while mood was related both to HADS depression and
anxiety. This result is partially in line with what was re-
ported by Patrick-Miller et al. [21], who found DT to be
anxiety-related rather than depression-related. When ex-
amining the intercorrelation of DT and MT with the single
HADS anxiety and depression items, some items of the
HADS scales seemed to be more representative of the sub-
jective evaluation of the single dimensions, such as the DT
and theMT, while other HADS items were less significantly
associated with the DT and MT. In general, however, MT
performed better and showed higher correlationwith anxiety
and depression than did DT. This could be related to trans-
lation problems, as already found for other psychosocial
dimensions of cancer [23] and the difficulty of finding an
exact match for the word “distress” in Italian, Spanish, and
Portuguese. In contrast, the word depression seems to have
no problem in being understood. Cross-cultural compar-
isons between studies using the DT [19, 21, 22] could
clarify part of these findings.
As far as psychosocial morbidity is concerned, when
using the standard cutoff scores for the HADS, as the
literature has repeatedly suggested as criteria for identify-
ing cases, 17.6% appeared to be borderline cases of anx-
iety and 15.4% borderline cases of depression. Moreover,
17.3% and 9% of patients appeared to have more severe
states of anxiety and depression, respectively (cutoff=11).
For general psychosocial morbidity (HADS total score),
28.8% of patients (n=90/312) were classified as being
cases (cutoff >14) while the rate of more severe general
caseness (cutoff=19) was 16.3%. These data confirm data
reported by other authors who indicated an average prev-
alence ranging from 15% to 25% [5, 6]. ROC analysis was
helpful in identifying the best cutoff scores on DT and MT
in detecting cases according to the HADS. More signif-
icant sensitivity and specificity levels were found on MT
than DT in detecting both general morbidity and more
severe caseness. On the whole, the best cutoff scores on
DT were 4 (general morbidity) and 5 (more severe case-
ness) while the best cutoff scores on MT were 3 (general
morbidity) and 4 (more severe caseness). With regard to
DT, these findings confirm the results obtained by Jacobsen
et al. [18], who showed that a cutoff score of 4 on DT was
related to caseness as measured by both the HADS and the
BSI. By using the cutoff of 5 among prostate cancer
patients, Roth et al. [17] showed that 31% were cases who



















Fig 2 Receiver operating characteristics (ROC) curve of the DT
(squares) and MT (circles) in detecting more severe caseness ac-
cording to the Hospital Anxiety and Depression Scale (HADS)
(cutoff=19)
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percent of DT cases received a DSM-IV psychiatric diag-
nosis. However, to our knowledge, no data are available
in the literature regarding the use of a different thermom-
eter, such as the MT, in detecting HADS caseness.
Some issues remain to be explored. Inclusion criteria in
this study (i.e., outpatients with a good performance status)
prevented us from drawing conclusions for patients with
more advanced disease, for those admitted to the hospital,
and for those followed at a domiciliary level. The usefulness
of DT or MT in these settings in southern Europe should
be examined. In this respect, Chochinov et al. [39] showed
that a single-item screening correctly identified depressed
cancer patients outperforming psychometric questionnaires,
such as the BDI, among advanced cancer patients. A further
aspect refers to the fact that the study was carried out in
only three centers and on a small sample of patients. In-
volvement of other centers in different countries and a
larger patient population would have been more significant
in terms of statistical analysis and clinical implications.
In conclusion, this study showed that the DT measuring
distress and a new tool, the MT measuring depression,
were valid instruments in detecting cancer patients who
were cases or severe cases according to the HADS, with a
tendency of the MT to perform better than the DT. Overall,
the findings of this study might have practical implication
in daily clinical activity and facilitate oncologists and
nurses in focusing attention on psychosocial dimensions of
cancer, in using simple tools to assess these dimensions in
follow-up visits, and in improving the referral process. The
possibility of misclassifying patients should, however,
always be considered as a limitation of short screening
instruments.
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